Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies

Calleja, José Luís; Albillos, Agustı́n; Cacho, Guillermo; Iborra, Jerónimo; Abreu, Luís; Escartín, P

doi:10.1016/s0168-8278(96)80009-2

Cited by 56 publications

(31 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One study demonstrated increased alanine aminotransferase levels with prednisone treatment and decreased transaminase and HCV RNA levels with ␣-Ifn in HCV infection. 2 The optimal treatment for CryP is unknown. Several uncontrolled reports suggest a beneficial response of prednisone, plasmapheresis, and other immunosuppressants.…”

Section: Discussionmentioning

confidence: 99%

Treatment of mononeuropathy multiplex in hepatitis C virus and cryoglobulinemia

1998

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Treatment of mononeuropathy multiplex in hepatitis C virus and cryoglobulinemia

1998

View full text Add to dashboard Cite

“…Posttransplantation HCV RNA levels have been similar among patients receiving tacrolimus and steroids and patients receiving cyclosporine A and steroids. 21,24,28 In the nontransplantation setting, corticosteroids are known to increase levels of hepatitis C viremia 29,30 and to be associated with more severe patterns of histo- …”

Section: Corticosteroid Treatment For Acute Cellular Rejection Is Assmentioning

confidence: 99%

Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence

Charlton

2003

Liver Transplantation

View full text Add to dashboard Cite

A lthough the impact of hepatitis C virus (HCV) infection on allograft histology varies substantially, 1-7 allograft failure secondary to recurrence of HCV is the most common cause of death and retransplantation among recipients with HCV. 8 In HCV and in other viral infections, including HIV 9 and hepatitis B, 10 analysis of viral dynamics has not only been helpful in understanding pathogenesis of infection but also in determining responsiveness to therapies. To date there have been relatively few studies of detailed viral kinetics after liver transplantation.All of the HCV kinetics studies that have been carried out to date have been in the nontransplantation setting and have relied on indirect measures of viral turnover incorporating mathematical models that are dependent on assumptions regarding the number of infected hepatocytes, interferon mechanisms of action, and efficacy. [11][12][13][14][15] Although these studies have undoubtedly provided insight into HCV kinetics, the reported half life (t 1/2 ) of hepatitis C virions has varied greatly among studies. Neumann et al reported the virion t 1/2 to be 2.7 hours, with production and clearance rates of 10 12 virions/day. 12 In contrast, Zeuzem et al reported the t 1/2 of hepatitis C to be 64.8 hours and clearance rates to be 6.7 ϫ 10 10 virions/day. 14 Both the Neumann and Zeusem manuscripts include discussions of the limitations of the techniques and models that were used, including the inability to discriminate between inhibition of HCV uptake into hepatocytes and inhibition of HCV RNA replication in de novo infected cells. In addition, all reports of HCV dynamics have relied on the serial determination of HCV RNA levels as a surrogate of HCV synthesis. Inherent to these methods is the unproven and unlikely assumption that viral synthesis is completely inhibited after initiation of interferon therapy. These limitations notwithstanding, important insights into the natural history of posttransplantation HCV infection can be distilled from the analysis of posttransplantation viral kinetics. The Impact of Liver Transplantation on Levels of Hepatitis C Viremia Early KineticsAlthough the interval between liver transplantation and clinical allograft infection varies, negative-strand HCV RNA, the putative sine que non of HCV replication, has been detected very early in the posttransplantation course. 16,17 Using a semiquantitative strand-specific reverse transcriptase-polymerase chain reaction in 23 liver transplant recipients with HCV infection, Negro et al were able to detect intrahepatic negative-strand HCV RNA as early as 7 days after liver transplantation. 17

show abstract

“…Because interferon (IFN) therapy for chronic HCV can trigger latent AIH and lead to severe hepatic failure, there are significant concerns about its use in patients with preexisting autoimmune processes [5] . Immunosuppression, on the hand, has an adverse effect on viral replication [6] . In this report, we present three patients with AIH/hepatitis C overlap syndrome in whom both processes rapidly responded to interferon-free antiviral therapy.…”

Section: Introductionmentioning

confidence: 99%

Direct acting antiviral therapy is curative for chronic hepatitis C/autoimmune hepatitis overlap syndrome

Sahebjam

Hajdu

Nortey

et al. 2016

WJH

View full text Add to dashboard Cite

Autoimmune phenomena are common in patients with chronic hepatitis C. Management of chronic hepatitis C/ autoimmune hepatitis syndrome has until recently been problematic due to the adverse effects of interferon on autoimmune processes and immunosuppression on viral replication. In this report we describe 3 patients with chronic hepatitis C/autoimmune hepatitis overlap syndrome who responded rapidly to direct acting antiviral therapy. The resolution of the autoimmune process supports a direct viral role in its pathophysiology.

show abstract

Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies

Cited by 56 publications

References 26 publications

Treatment of mononeuropathy multiplex in hepatitis C virus and cryoglobulinemia

Treatment of mononeuropathy multiplex in hepatitis C virus and cryoglobulinemia

Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence

Direct acting antiviral therapy is curative for chronic hepatitis C/autoimmune hepatitis overlap syndrome

Contact Info

Product

Resources

About